Navigation Links
PreMD Initiates FDA Review Process and Provides Corporate Update
Date:2/12/2008

TORONTO, Feb. 12 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today provided an update on the company's business direction in light of the recent decision from the U.S. Food and Drug Administration (FDA).

Appeal to the FDA

PreMD today filed a request for a second level review of the 510(k) submission, in accordance with the following Code of Federal Regulations 21 CFR part 10.75(c). As announced on Jan. 15, the company received a non-substantially equivalent (NSE) letter from the FDA regarding the 510(k) submission for an expanded regulatory claim on its point-of-care (POC) skin cholesterol test. PreMD continues to believe that its skin cholesterol test merits 510(k) clearance. "We have acted as quickly as possible in initiating the process and will continue to evaluate the best strategies to help achieve FDA clearance," said Brent Norton, president and chief executive officer of PreMD. PreMD is working with AstraZeneca Pharmaceuticals, which has licensed the test for marketing and distribution in the United States, to fully explore the issues raised by the FDA and address the appropriate steps going forward.

Additional Company Information

In light of PreMD's financial status, the company also has taken actions to maximize company value. These actions include a workforce reduction of approximately 33% and other general and administrative expense decreases. The key members of PreMD are concentrating their efforts on the FDA review and assessing strategic alternatives to maximize shareholder value. PreMD will continue to realign its organization and optimize the company's cost structure and cash resources. PreMD continues to advance the development programs for other product candidates in its oncology pipeline, which remain unaffected by the FDA decision.

PreMD also recently appointed Ronald Henriksen as Chair of the Audit Committee. Mr. Henriksen has been a director of PreMD since 2004 and is the chief investment officer of Twilight Ventures.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a test designed for use in the life insurance industry. The company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

(x) Trademark


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PreMD Provides Update on 510(k) Application for PREVU(x) POC
2. PreMD Inc. Provides Corporate Update
3. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
4. PreMD Announces FDA Decision on POC Skin Cholesterol Test
5. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
8. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
9. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
10. Harbinger Research Initiates Coverage on HearAtLast
11. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... US Sports Camps , official operators of Nike Yoga Camps, ... yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England city ... Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The American public ... such water may be safer than regular municipal or well water. The recent experience ... host Sharon Kleyne, could go a long way toward increasing public acceptance of recycled ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced ... and donate to Give To Cure’s campaign that is crowdfunding clinical trials to help ... and share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli ... Cost Dental Day to individuals in need. The event is scheduled to take place ... Dental Day is to provide dental care to community members in need. Each patient ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Md. , Feb. 4, 2016 In response ... , the FDA,s Deputy Commissioner for Medical Products and Tobacco, ... plan to reassess the agency,s approach to opioid medications. The ... while still providing patients in pain access to effective relief. ... FDA will: , Re-examine the risk-benefit paradigm for ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
(Date:2/4/2016)... , Feb. 4, 2016 SONIFI™ Health, ... solutions, today announced that MonteCedro, an innovative retirement ... Engagement System. The system provides a simple and ... access through a tablet PC. ... engagement system provides access to a wide spectrum ...
Breaking Medicine Technology: